Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

L'uso dell'iniezione intra-articolare di corticosteroidi per trattare l'artrosi dell'articolazione carpometacarpale

6 novembre 2026 aggiornato da: University of Alberta

L'uso dell'iniezione intra-articolare di corticosteroidi per trattare l'artrosi dell'articolazione carpometacarpale: uno studio di controllo randomizzato

This randomized clinical trial (RCT) will evaluate 6-month outcomes following intra-articular injections for arthritis of the thumb carpometacarpal (CMC) joint by comparing corticosteroid plus local anesthetic versus saline (placebo) plus local anesthetic.

Panoramica dello studio

Descrizione dettagliata

Background & Significance:

The burden of chronic diseases such as osteoarthritis (OA) is increasing globally, having a major impact on both health services and society. 1,2 The CMC joint of the thumb is the most commonly affected joint in the upper extremity by OA, and may lead to pain, decreased hand function and poor health-related quality of life. 3-6 The prevalence of CMC OA varies depending on the population being studied and is not yet well defined. Haara et al. 6 reported age-adjusted CMC OA prevalence of 7% in men and 15% in women among adults thirty years of age or older in Finland. The ROTTERDAM study7 showed that 67% of the women and 54.8% of the men had OA in at least one hand joint, with 35.8% occurring at the CMC joint. The Framingham Study reported higher prevalence of symptomatic hand OA in women (26.2%) compared to men (13.4%) aged 70 year or older. Symptomatic participants in this cohort had 10% reduced maximal grip strength, reported more difficulty with activities of daily living such as writing, handling, or fingering small objects (odds ratio = 3.4), and increased difficulty lifting over 10-pound objects (odds ratio = 1.7 and 1.6, respectively).8

Treating CMC OA is challenging, since evidence is contradictory. A study looking at the natural history of hand OA over a 6 year period showed variation in pain and functional changes, with half of the population reporting deterioration of symptoms and the other half reporting improvements of outcomes with different treatments. 9 Clinical changes (pain and function) and radiographic progression of CMC OA were not related in this study. 9 Non-operative management (i.e. splints, medications, physiotherapy) is usually the first choice of treatment for symptomatic CMC OA, followed by surgery if failed non-operative management. 3,10 Current non-operative guidelines for treatment of hand OA are based on a combination of research findings and expertise opinion. 11-13 2007EULAR, 2012 American College of Rheumatology and 2014 NICE guidelines recommendations for the treatment of hand OA include general considerations (i.e. clinical presentation, risk factors and associated diseases), non-pharmacological (i.e. splint, education, exercises, thermal modalities), and pharmacological (i.e. pain medications, oral and topical anti-inflammatories, opioids) approaches. 11-13 2007EULAR and 2014 NICE also recommend intra-articular corticosteroid injections as an adjunct treatment if patients didn't respond to other treatment approaches, even though evidence is weak.11,13

Effectiveness of guided intra-articular injections for CMC OA evidence is inconsistent. There is only one published RCT looking specifically at efficacy of corticosteroid injections in CMC OA that found no clinical benefit from intra-articular corticosteroid injection to moderate to severe CMC OA compared with placebo injection. This study ended earlier due to recruitment issues and is underpowered to detect true differences between groups. 14 A meta-analysis investigating intra-articular injections of corticosteroids or hyaluronic acid in thumb OA stated that corticosteroids may be helpful in decreasing pain and hyaluronic acid in improving pulp pinch force in a period of 5 to 6 months. 15 Due to high heterogeneity of included studies in this meta-analysis, the evidence is still inconclusive. Another RCT compared the efficacy of intra-articular hyaluronic acid and corticoid injections in CMC OA and found that both study groups had decreased pain and improved function when compared to baseline data, with no significant differences between groups. 16 A recent systematic review on non-surgical therapies for hand OA found inconsistent evidence when comparing intra-articular steroids and placebo. 17 They found three RCTs comparing intra-articular steroids to placebo, with two studies showing no difference and one study showing significant improvement in pain with movement between groups.17

Based on the lack of strong evidence regarding the use of guided corticosteroid injections to treat CMC OA, this randomized clinical trial (RCT) will compare 6-months outcomes following fluoroscopic guided injections of corticosteroid plus local anesthetic or saline (placebo) plus local anesthetic in adult participants with carpometacarpal osteoarthritis (OA).

Our hypothesis is that participants undergoing guided intra-articular corticosteroid injections will have better outcomes in the short -term, but not at the long term when compared to the saline group.

Research Design & Methods:

Design: Randomized Control Trial, Chart Review Sample Size: Sample size was calculated based on repeated measures ANOVA model with 2 groups and 4 time points (longitudinal approach), and group effect (between subject effect) were examined for power analysis. Effect size (Cohen's f) was considered from f=0.10 (small effect) to f=0.40 (large effect) increased by 0.05. Few different correlations among repeated measures were considered (r=0.3 to 0.6 by 0.1). Based on effect size f=0.25 (medium effect), approximately 62 to 90 participants will be required as total sample size, with approximately 31to 45 participants per group.

Enrollment Procedures: Eligible participants presenting to primary care, rheumatologists or a surgical consult will be introduced to the study. If the participant expresses interest, the participant will complete the contact information form (assent to contact) and the Research Coordinator will be notified. The Research Coordinator will contact the participant to discuss the study in detail, obtain informed consent and book a baseline assessment.

Baseline Evaluation: Consented participants will undergo a baseline assessment with the research coordinator who will be blinded to the treatment allocation. The assessment will consist of 1) Quick-DASH, 2) Brief Michigan Hand Outcomes Questionnaire (Brief MHQ), 3) pinch strength using a handheld dynamometer, 4) socio-demographics (age, gender, height, weight, handedness, smoking status, work/recreational sports information, duration of symptoms, type of onset (insidious / traumatic) data, and 5) thumb range of motion (ROM). The participant will also complete the Visual Analogue Scale (VAS) for pain intensity (rest and movement), and concomitant treatments form (medications, splints, physiotherapy). A chart review of the radiographs used for participant eligibility will be performed to confirm the grade of osteoarthritis.

Randomization:

Participants will be randomized to one of the two groups once eligibility is confirmed and participant is agreeable to be part of the study: Group A (intra-articular corticosteroid injection + local anesthetic) or Group B (saline injection + local anesthetic). The randomization sequence will be computer-generated in uneven blocks. Randomization codes will be stored in opaque sequentially numbered envelopes and will be opened at baseline assessment session. Participants and outcomes assessor will be blinded to the type of injection they will be receiving.

Interventions:

  • Fluoroscopic Guided Intra-articular Corticosteroid Injection plus local anesthetic: Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected. The surgeon and the participant will be blinded to the injection content.
  • Fluoroscopic Guided Intra-articular Saline Injection plus local anesthetic: Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected. The surgeon and the participant will be blinded to the injection content.

Follow-ups:

Follow-up research assessments will occur at:

• 6 weeks, 3- and 6-months: Assessment will be done by the research coordinator and will include 1) Quick-DASH, 2) Brief MHQ, 3) Pinch strength, 4) Pain at rest and with movement, 5) Concomitant treatments tracking, 6) Thumb ROM.

The outcome assessor will be blinded to group allocation at all assessments points.

Outcomes/ Outcome Measures:

  • Primary:

    o Pain with movement at 3 months- Pain will be assessed using Visual Analogue Scale (VAS) where zero equaled no pain and 10 the worst possible pain.18,19 VAS is a reliable and valid method of measuring patient-reported pain and a minimal difference of 20 mm (20%) among groups will be considered clinically important.20-22

  • Secondary Outcomes:

    • Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH) Questionnaire: it's a 11-item, patient-reported questionnaire that measures the function and psychosocial impact of upper extremity musculoskeletal conditions in patients' quality of life. It is scored between 0 (no disability) and 100(very disable).23 The Quick-DASH has been widely used in clinical practice and research as a valid, reliable and responsive tool to measure treatment outcomes from the patient's perspective after upper limb injuries.24 The minimal important change expected is a 10-point difference in mean DASH score among groups.24
    • Brief Michigan Hand Outcomes Questionnaire (Brief MHQ): It is a 12-item self-administered questionnaire that assess function, appearance, pain, and satisfaction in patients with hand and wrist conditions and injuries, including arthritis.
    • Pinch Strength: Pinch strength will be measured with a mechanical pinch gauge that is a reliable and valid method to detect difference in thumb strength.26 Pinch strength will be measured using the following standard positions: 1) Tip pinch: pinch between the thumb and index finger, and 2) Tripod pinch: pinch between the thumb, index and middle fingers.26 A minimal difference of 0.33 kg for tip and 0.35 kg for tripod pinch among groups will be considered clinically important.26
    • Thumb Range of Motion: Thumb range of motion at the metacarpal-phalangeal joint will be measured with a goniometer for passive flexion and extension (degrees). Goniometric measurement of the thumb is used as a common outcome measure in people with thumb CMC OA.27
    • Conversion to Surgery: An assessment of how many participants elected to proceed with surgery by December 31, 2025.

Statistical Analysis: Statistical analysis will use Intention-to-Treat approach with all outcomes attributed to the assigned group. Descriptive statistics will be used for group comparisons with independent t-tests for continuous and Pearson Chi-square or Fisher's Exact tests for categorical variable at baseline and for possible complications/adverse events. Linear Mixed Modeling (LMM), adjusted for gender and employment, will compare pain, Quick-Dash, Brief MHQ and pinch strength between groups over the 6-months evaluation period. The level of significance will be set at α=0.05. Statistical analysis will use the following software: SPSS version 25.0, SAS version 9.4, and R version 3.5.2.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

61

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Alberta
      • St. Albert, Alberta, Canada, T8N 6C4
        • Western Hand & Upper Limb Facility, Sturgeon Community Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participants must be 18 years old or older at recruitment
  • Present clinical and radiographic signs of thumb CMC OA using the American College of Rheumatology (ACR) criteria for the classification of hand osteoarthritis.

Exclusion Criteria:

  • History of inflammatory arthritis
  • Previous steroid joint injection to either thumb CMC joint
  • Pregnancy or breastfeeding
  • Psychiatric illness
  • Cognitive impairment, or health conditions that preclude informed consent or receiving the injection
  • People who do not speak/read/understand English, have no fixed address or contact, or are unwilling to complete follow-ups

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Corticosteroid Injection

Pre-filled opaque syringe containing 40 mg (1cc) of depo-medrol combined with 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using fluoroscopic imaging to ensure injection into the joint. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.

Corticosteroid

Comparatore placebo: Saline

Pre-filled opaque syringe containing 0.5 cc of 1% lidocaine (or 1cc saline + 0.5 cc 1% lidocaine) will be injected in the symptomatic CMC joint using ultrasound imaging to ensure accuracy of injected location. If both CMC joints are symptomatic, the most symptomatic joint will be injected. If both CMC joints are equally symptomatic, the dominant hand will be injected.

Placebo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Pain with movement
Lasso di tempo: baseline, 6 weeks, 3 months, 6 months

Pain will be assessed using Visual Analogue Scale (VAS) where zero equaled no pain and 10 the worst possible pain. a minimal difference of 20 mm (20%) between groups will be considered clinically important.

baseline, 6 weeks, 3 months, 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH) Questionnaire
Lasso di tempo: baseline, 6 weeks, 3 months, 6 months

it's a 11-item, patient-reported questionnaire that measures the function and psychosocial impact of upper extremity musculoskeletal conditions in patients' quality of life. It is scored between 0 (no disability) and 100(very disable). The minimal important change expected is a 10-point difference in mean DASH score among groups.

baseline, 6 weeks, 3 months, 6 months
Change in Brief Michigan Hand Outcomes Questionnaire
Lasso di tempo: baseline, 6 weeks, 3 months, 6 months

Brief Michigan Hand Outcomes Questionnaire (Brief MHQ): It is a 12-item self-administered questionnaire that assess function, appearance, pain, and satisfaction in patients with hand and wrist conditions and injuries, including arthritis.

baseline, 6 weeks, 3 months, 6 months
Change in Pinch Strength
Lasso di tempo: baseline, 6 weeks, 3 months, 6 months

Pinch strength will be measured with a mechanical pinch gauge that is a reliable and valid method to detect difference in thumb strength. Pinch strength will be measured using the following standard positions: 1) Tip pinch: pinch between the thumb and index finger, and 2) Tripod pinch: pinch between the thumb, index and middle fingers. A minimal difference of 0.33 kg for tip and 0.35 kg for tripod pinch among groups will be considered clinically important.

baseline, 6 weeks, 3 months, 6 months
Thumb Range of Motion
Lasso di tempo: Baseline, 6 weeks, 3 months, 6 months

Thumb range of motion at the metacarpal-phalangeal joint will be measured with a goniometer for passive flexion and extension (degrees). Goniometric measurement of the thumb is used as a common outcome measure in people with thumb CMC OA.

Baseline, 6 weeks, 3 months, 6 months
Conversion to Surgery
Lasso di tempo: From enrollment to December 31, 2025.

An assessment of how many participants elected to proceed with surgery by December 31, 2025.

From enrollment to December 31, 2025.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 dicembre 2020

Completamento primario (Effettivo)

29 settembre 2025

Completamento dello studio (Effettivo)

31 dicembre 2025

Date di iscrizione allo studio

Primo inviato

21 novembre 2019

Primo inviato che soddisfa i criteri di controllo qualità

22 novembre 2019

Primo Inserito (Effettivo)

26 novembre 2019

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi